Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bayer AG is conducting an observational study titled ‘SMART-Finder – Identification of Patients With Elevated UACR Levels in a T2DM Cohort.’ The study aims to identify patients with type 2 diabetes mellitus (T2DM) who have elevated levels of albumin in their urine, a potential indicator of kidney damage. This research is significant as it seeks to understand the prevalence and progression of kidney complications in T2DM patients using the myTherapy app in Germany.
The study examines the use of Finerenone (Kerendia, BAY94-8862) and other T2DM drugs prescribed by physicians. These interventions are intended to manage T2DM and its complications, including chronic kidney disease.
The study is designed as an observational cohort study, focusing on real-world data collection without specific interventions. Participants’ urine albumin-creatinine ratio (UACR) levels are measured by their physicians during routine care, with data collected via the myTherapy app.
The study began on August 18, 2023, with data collection running from October 2022 to December 2024. The primary completion date is not specified, but the last update was submitted on August 12, 2025. These dates are crucial as they indicate the timeline for data collection and analysis.
This study could impact Bayer’s stock performance by showcasing its commitment to addressing complications in T2DM, potentially enhancing investor confidence. The focus on real-world data may also provide Bayer a competitive edge in the pharmaceutical industry, particularly in the management of diabetes-related kidney issues.
The study is ongoing, with further details available on the ClinicalTrials portal.